CD19 CAR-T cells is named as a drug or biological intervention in 4 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Hebei Senlang Biotechnology Inc., Ltd. (1), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) and Beijing GoBroad Hospital (1). Registered phases: Phase 1/2 and Phase 2. Conditions studied include Autoimmune Diseases; B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma Refractory.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04661020 | CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma (ClinicalTrials.gov ↗) Large B-Cell Lymphoma (LBCL) |
Phase 2 | Recruiting |
| NCT06688799 | Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases (ClinicalTrials.gov ↗) Autoimmune Diseases |
Phase 1/2 | Recruiting |
| NCT07161193 | Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases (ClinicalTrials.gov ↗) Autoimmune Diseases |
Phase 1/2 | Not yet open |
| NCT06220097 | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies (ClinicalTrials.gov ↗) B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Autoimmune Diseases | 2 |
| B-cell Acute Lymphoblastic Leukemia | 1 |
| B-cell Lymphoma Refractory | 1 |
| Large B-Cell Lymphoma (LBCL) | 1 |
| Lead sponsor | Trials |
|---|---|
| Hebei Senlang Biotechnology Inc., Ltd. | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Beijing GoBroad Hospital | 1 |
| Zhejiang University | 1 |
| Register | CD19 CAR-T cells trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CD19 CAR-T cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CD19 CAR-T cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.